Avax Technologies Inc., a Philadelphia-based immunotherapy specialist that ran into financing troubles in 2009, has settled debts it owed the Cancer Treatment Centers of America Inc. (CTCA) and Firebird Management LLC, repaying both parties with equity as it advances plans to re-launch a pivotal clinical study of M-Vax, its candidate immunotherapy for melanoma, and explore resuming a trial of O-Vax, a potential immunotherapeutic vaccine to treat ovarian cancer.